TSC2 Deficiency Unmasks a Novel Necrosis Pathway That Is Suppressed by the RIP1/RIP3/MLKL Signaling Cascade.

Tuberous sclerosis complex (TSC) is a genetic multiorgan disorder characterized by the development of neoplastic lesions in kidney, lung, brain, heart, and skin. It is caused by an inactivating mutation in tumor suppressor genes coding the TSC1/TSC2 complex, resulting in the hyperactivation of mTOR- and Raf/MEK/MAPK-dependent signaling that stimulates tumor cell proliferation and metastasis. Despite its oncogenic effect, cells with TSC deficiency were more sensitive to oxidative stress and dependent on mitochondrial metabolism, providing a rationale for a new therapeutic approach. The current study shows that simultaneous inhibition of two major pathways regulating redox homeostasis using l-buthionine-sulfoximine (BSO, glutathione synthesis inhibitor) and auranofin (thioredoxin reductase inhibitor) induces oxidative burst, mitochondrial damage, and necrotic cell death in TSC-deficient cells in a highly synergistic and cell context-specific manner. Furthermore, blocking RIP1/RIP3/MLKL-dependent signaling using chemical inhibitors necrostatin-1 (Nec-1) and necrosulfonamide (NSA) synergizes with BSO and auranofin in killing TSC-deficient cells. Expression analysis demonstrated that RIP1, RIP3, and MLKL protein levels are elevated in cells with TSC2 deficiency, and their inactivation enhances mitochondrial dysfunction in a glutaminolysis-dependent and autophagy-independent manner. Finally, supplementation with the mitochondrial metabolite α-ketoglutarate, whose synthesis is regulated by RIP1/RIP3/MLKL, rescues cells from the sensitizing effect of Nec-1 and NSA. Together, this study identifies a previously unrecognized novel regulated necrotic death pathway that involves mitochondrial homeostasis, is suppressed by the RIP1/RIP3/MLKL signaling in TSC-deficient cells, and could be a promising therapeutic target for TSC-associated tumors. Cancer Res; 76(24); 7130-9. ©2016 AACR.

[1]  S. Kang,et al.  Glutaminolysis as a target for cancer therapy , 2016, Oncogene.

[2]  G. Shu,et al.  Alpha-ketoglutarate promotes skeletal muscle hypertrophy and protein synthesis through Akt/mTOR signaling pathways , 2016, Scientific Reports.

[3]  K. Kotulska,et al.  The Role of mTOR Inhibitors in the Treatment of Patients with Tuberous Sclerosis Complex: Evidence-based and Expert Opinions , 2016, Drugs.

[4]  P. Zou,et al.  Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer , 2015, Oncotarget.

[5]  P. Campbell,et al.  Somatic mutation in cancer and normal cells , 2015, Science.

[6]  E. Aronica,et al.  Tuberous sclerosis complex neuropathology requires glutamate-cysteine ligase , 2015, Acta Neuropathologica Communications.

[7]  J. Silke,et al.  The diverse role of RIP kinases in necroptosis and inflammation , 2015, Nature Immunology.

[8]  A. Thorburn,et al.  RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis , 2015, EMBO reports.

[9]  J. Moss,et al.  Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis , 2015, Clinical epidemiology.

[10]  Christine Roder,et al.  Auranofin: Repurposing an Old Drug for a Golden New Age , 2015, Drugs in R&D.

[11]  Jianhua Yao,et al.  Sustained effects of sirolimus on lung function and cystic lung lesions in lymphangioleiomyomatosis. , 2014, American journal of respiratory and critical care medicine.

[12]  J. Asara,et al.  High-Throughput Drug Screen Identifies Chelerythrine as a Selective Inducer of Death in a TSC2-null Setting , 2014, Molecular Cancer Research.

[13]  M. C. Pistoresi-Palencia,et al.  Oxidative stress, cell cycle arrest and differentiation contribute toward the antiproliferative action of BSO and calcitriol on Caco-2 cells , 2014, Anti-cancer drugs.

[14]  R. Nussbaum,et al.  Renal Cell Carcinoma in Tuberous Sclerosis Complex , 2014, The American journal of surgical pathology.

[15]  J. Blenis,et al.  Estradiol promotes pentose phosphate pathway addiction and cell survival via reactivation of Akt in mTORC1 hyperactive cells , 2014, Cell Death and Disease.

[16]  M. Sahin,et al.  Mechanism-based treatment in tuberous sclerosis complex. , 2014, Pediatric neurology.

[17]  F. Chan,et al.  Necrosis-dependent and independent signaling of the RIP kinases in inflammation. , 2014, Cytokine & growth factor reviews.

[18]  G. Kroemer,et al.  Dimethyl α-ketoglutarate inhibits maladaptive autophagy in pressure overload-induced cardiomyopathy , 2014, Autophagy.

[19]  S. Leng,et al.  Abstract B27: RIP1 maintains DNA integrity and cell proliferation by regulating PGC-1α-mediated mitochondrial oxidative phosphorylation and glycolysis , 2015 .

[20]  A. Choi,et al.  Autophagy-Dependent Metabolic Reprogramming Sensitizes TSC2-Deficient Cells to the Antimetabolite 6-Aminonicotinamide , 2013, Molecular Cancer Research.

[21]  F. Zwartkruis,et al.  Rheb and mammalian target of rapamycin in mitochondrial homoeostasis , 2013, Open Biology.

[22]  S. Amin,et al.  RIP1 potentiates BPDE-induced transformation in human bronchial epithelial cells through catalase-mediated suppression of excessive reactive oxygen species. , 2013, Carcinogenesis.

[23]  R. O'Regan,et al.  Everolimus: side effect profile and management of toxicities in breast cancer , 2013, Breast Cancer Research and Treatment.

[24]  P. Vandenabeele,et al.  Necrostatin-1 blocks both RIPK1 and IDO: consequences for the study of cell death in experimental disease models , 2012, Cell Death and Differentiation.

[25]  E. Henske,et al.  Lymphangioleiomyomatosis - a wolf in sheep's clothing. , 2012, The Journal of clinical investigation.

[26]  C. Knudson,et al.  Susceptibility of Human Head and Neck Cancer Cells to Combined Inhibition of Glutathione and Thioredoxin Metabolism , 2012, PloS one.

[27]  A. Ferrari,et al.  mTOR signaling pathway and mTOR inhibitors in cancer therapy. , 2012, Hematology/oncology clinics of North America.

[28]  M. Kohrman.  Emerging treatments in the management of tuberous sclerosis complex. , 2012, Pediatric neurology.

[29]  Helmut Neumann,et al.  Caspase-8 regulates TNF-alpha induced epithelial necroptosis and terminal ileitis , 2011, Nature.

[30]  J. Manola,et al.  Multicenter Phase 2 Trial of Sirolimus for Tuberous Sclerosis: Kidney Angiomyolipomas and Other Tumors Regress and VEGF- D Levels Decrease , 2011, PloS one.

[31]  D. Spitz,et al.  Enhancement of Carboplatin-Mediated Lung Cancer Cell Killing by Simultaneous Disruption of Glutathione and Thioredoxin Metabolism , 2011, Clinical Cancer Research.

[32]  D. Kwiatkowski,et al.  Tumorigenesis in tuberous sclerosis complex is autophagy and p62/sequestosome 1 (SQSTM1)-dependent , 2011, Proceedings of the National Academy of Sciences.

[33]  I. Pascual-Castroviejo,et al.  Neurosurgical treatment of tuberous sclerosis complex lesions , 2011, Child's Nervous System.

[34]  B. Viollet,et al.  Phosphorylation of ULK1 (hATG1) by AMP-Activated Protein Kinase Connects Energy Sensing to Mitophagy , 2011, Science.

[35]  E. Thiele,et al.  Tuberous Sclerosis Complex: Diagnostic Challenges, Presenting Symptoms, and Commonly Missed Signs , 2011, Pediatrics.

[36]  R. Schwartz,et al.  Tuberous sclerosis complex: tumors and tumorigenesis , 2011, International journal of dermatology.

[37]  Xingshun Xu,et al.  Synergistic protective effects of humanin and necrostatin-1 on hypoxia and ischemia/reperfusion injury , 2010, Brain Research.

[38]  Sang Gyun Kim,et al.  Glucose addiction of TSC null cells is caused by failed mTORC1-dependent balancing of metabolic demand with supply. , 2010, Molecular cell.

[39]  Wim Declercq,et al.  Tumor necrosis factor-mediated cell death: to break or to burst, that’s the question , 2010, Cellular and Molecular Life Sciences.

[40]  Na Zhang,et al.  RIP3, an Energy Metabolism Regulator That Switches TNF-Induced Cell Death from Apoptosis to Necrosis , 2009, Science.

[41]  D. Kwiatkowski,et al.  Tuberous Sclerosis Complex Activity Is Required to Control Neuronal Stress Responses in an mTOR-Dependent Manner , 2009, The Journal of Neuroscience.

[42]  E. Henske,et al.  Estrogen promotes the survival and pulmonary metastasis of tuberin-null cells , 2009, Proceedings of the National Academy of Sciences.

[43]  S. Habib.  Insight into mechanism of oxidative DNA damage in angiomyolipomas from TSC patients , 2009, Molecular Cancer.

[44]  B. Manning,et al.  The TSC1-TSC2 complex: a molecular switchboard controlling cell growth. , 2008, The Biochemical journal.

[45]  V. Mootha,et al.  mTOR controls mitochondrial oxidative function through a YY1–PGC-1α transcriptional complex , 2007, Nature.

[46]  F. Tamanoi,et al.  Increased Rheb-TOR signaling enhances sensitivity of the whole organism to oxidative stress , 2006, Journal of Cell Science.

[47]  M. Berry,et al.  The responses of Ht22 cells to oxidative stress induced by buthionine sulfoximine (BSO) , 2005, BMC Neuroscience.

[48]  J. Herbert,et al.  Chelerythrine is a potent and specific inhibitor of protein kinase C. , 1990, Biochemical and biophysical research communications.